SRDAPRT

Sarda Proteins Share Price

₹107.85 0.00 (0.00%)

21 Nov, 2024 16:17

SIP TrendupStart SIP in SRDAPRT

Start SIP

Performance

  • Low
  • ₹0
  • High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹0
  • Open Price₹0
  • Previous Close₹0
  • Volume0

Investment Returns

  • Over 1 Month + 4.96%
  • Over 3 Month + 10.16%
  • Over 6 Month + 54.96%
  • Over 1 Year + 156.79%
SIP Lightning

Smart Investing Starts Here Start SIP with Sarda Proteins for Steady Growth!

Invest Now

Sarda Proteins Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

Sarda Proteins Financials

Sarda Proteins Technicals

EMA & SMA

Current Price
₹107.85
0 (0%)
  • stock-down_img
  • Bullish Moving Average 0
  • stock-up_img
  • Bearish Moving Average 0
  • 20 Day
  • ₹98.10
  • 50 Day
  • ₹83.17
  • 100 Day
  • ₹70.29
  • 200 Day
  • ₹62.24

Resistance and Support

107.85 Pivot Speed
  • R3 107.85
  • R2 107.85
  • R1 107.85
  • S1 107.85
  • S2 107.85
  • S3 107.85

What's your outlook on Sarda Proteins?

You can only vote for once

Sarda Proteins Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-08 Quarterly Results
2024-08-12 Quarterly Results
2024-04-30 Audited Results
2024-02-13 Quarterly Results
2023-11-07 Quarterly Results

Sarda Proteins F&O

Sarda Proteins Shareholding Pattern

No data available.

About Sarda Proteins

  • NSE Symbol
  • SRDAPRT
  • BSE Symbol
  • 519242
  • ISIN
  • INE995U01011

Similar Stocks to Sarda Proteins

Sarda Proteins FAQs

Sarda Proteins share price is ₹107 As on 21 November, 2024 | 16:03

The Market Cap of Sarda Proteins is ₹18.6 Cr As on 21 November, 2024 | 16:03

The P/E ratio of Sarda Proteins is 360.7 As on 21 November, 2024 | 16:03

The PB ratio of Sarda Proteins is 11.4 As on 21 November, 2024 | 16:03

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23